Kornimate/medical-research-clean huggingface dataset:
one sequencing find all for helicobacter pylori infection

Conditions: Helicobacter Pylori Infection; Resistant Infection

Summary: the aim of this study is to identify antibiotic resistance gene mutations in helicobacter pylori (hp) and genetic diversity of drug metabolism for antibiotics and proton pump inhibitors (ppis) in patients with hp infection using next-generation sequencing (ngs). the mutation of host/hp strain will be investigated by single ngs, and the eradication results according to genetic polymorphism of host/hp strain will be analyzed.

this study is a prospective observational study for the helicobacter pylori (hp) infected patients on typical gastroduodenoscopy (egd) at boramae hospital, seoul, korea. the presence of antibiotic resistance genes of hp and the diversity of the pharmacokinetic genotypes of the subjects will be investigated by performing single next-generation sequencing (ngs) analysis using gastric mucosal tissue samples of the hp infected subjects. the purpose of this study is to collect data on the antimicrobial resistance mutation of hp (23s rrna gene, pbp1 gene, rdxa, frxa, frxb gene, 16s rrna, gyra, gyrb gene, and cag a gene) and to investigate the genetic diversity on the metabolism of antibiotics and proton pump inhibitors (cyp enzyme) in a korean population. the investigators are going to compare the results of standard eradication therapy according to the resistance mutation of hp and drug genetic diversity of subjects.

Eligibility criteria:
inclusion criteria: * age over 18 years old * clo test positive * findings of gastric ulcer, atrophic gastritis on gastroduodenoscopy * agreed to hp eradication therapy and accept to follow-up * agreed to participating in the study exclusion criteria: * history of previous hp eradication treatment * history of partial gastrectomy

Keywords: whole genome sequencing polymorphism
impact of pharmaceutical interviews regarding the management of adverse effects related to the antibiotic therapy used to treat osteoarticular infections during return home

Conditions: Bone and Joint Infection

Summary: the primary objective is to evaluate the impact of pharmaceutical interviews in the patient self-management of non-severe side effects caused by antibiotics prescribed for the treatment of osteoarticular infections when the patient returns home.


Eligibility criteria:
inclusion criteria: * patient \> or =18 years; * informed consent signed; * french-speaking and reading; * affiliated to a social insurance; * benefiting from medical and surgical care for an osteoarticular infection; * treated with an oral antibiotic therapy on discharge from hospital. * indication of the antibiotic therapy osteoarticular infection; * return home immediately after discharge. exclusion criteria: * refusal to participate * protected adult patient, under guardianship or curatorship. * minor patient * patient benefiting from an ame. * pregnant or breastfeeding woman. * non-french speaking patient. * patient unable to understand the course of the study. * patient with a documented history of cognitive or psychiatric disorders. * patient treated with oral antibiotic therapy for an indication other than osteoarticular infection. * patient treated with parenteral antibiotic therapy. * discharge: institution (ehpad), rehabilitation or other health establishment. * patient systematically using one of the symptomatic treatments proposed in the discharge prescription before hospitalization.

Keywords: osteo articular infection adverse event antibiotic treatment pharmaceutical interview
effect of low-level laser therapy on post-bleaching sensitivity and color change

Conditions: Tooth Bleaching; Low-level Laser Therapy; Dentin Sensitivity; Clinical Trial

Summary: objective: the objective of this clinical study was to evaluate low-level laser (lll) therapy in tooth sensitivity and in effecting color change after in-officer bleaching treatment across three weeks of treatment. methods: twenty-one volunteers were evaluated through the split-mouth model, so that the right and left maxillary/mandibular quadrants were randomized and allocated to one of two groups: gplacebo - the laser tip was positioned without the emission of light (placebo effect) + tooth bleaching with 35% hydrogen peroxide (hp); glaser - treated with lll + tooth bleaching with 35% hp. to assess tooth sensitivity, a modified visual analogue scale (vas) was used after an evaporative stimulus (stimulated pain) and a daily pain questionnaire (unstimulated pain) was also applied. a spectrophotometer was used to measure the color. three bleaching sessions were performed, with intervals of 7 days. sensitivity results were tested using friedman test for intra-group evaluation and wilcoxon test for inter-group evaluation and anova for color change.

twenty-one volunteers were evaluated through the split-mouth model, so that the right and left maxillary/mandibular quadrants were randomized and allocated to one of two groups: gplacebo - the laser tip was positioned without the emission of light (placebo effect) + tooth bleaching with 35% hydrogen peroxide (hp); glaser - treated with lll + tooth bleaching with 35% hp. to assess tooth sensitivity, a modified visual analogue scale (vas) was used after an evaporative stimulus (stimulated pain) and a daily pain questionnaire (unstimulated pain) was also applied. a spectrophotometer was used to measure the color. three bleaching sessions were performed, with intervals of 7 days.

Eligibility criteria:
inclusion criteria: * do not have previous dental sensitivity * the canine had to be shade a2 or darker. exclusion criteria: * enamel hypoplasia * gingival recession * dentin exposure * visible cracks on buccal enamel * pulpitis

Keywords: laser color
vaginal cuff brachytherapy followed by chemotherapy in patients with endometrioid cancer

Conditions: Endometrial Cancer; Papillary Serous; Clear Cell Endometrial Cancer

Summary: the purpose of this study is to determine the progression-free survival of patients with surgically staged, stage i-ii papillary serous, clear cell, or endometrioid carcinomas with high-intermediate risk factors treated by vaginal cuff brachytherapy followed by chemotherapy.

all patients must have undergone complete surgical staging including bilateral pelvic and para-aortic lymphadenectomy. all patients will receive radiation therapy. treatment will be delivered either by ldr or hdr brachytherapy. the treatment plan must be started at the time of enrollment. the vaginal brachytherapy should be started within 4 weeks of surgery (within 2 weeks of enrollment), in order to avoid delays in initiation of systemic therapy, which should start on post-operative day 21. the dose will be prescribed to the vaginal (mucosal) surface as defined at the surface of the applicators. following vaginal cuff radiation therapy, all patients will receive chemotherapy.

Eligibility criteria:
inclusion criteria: * all patients must have undergone specified complete surgical staging. * patients must be surgically staged endometrial cancer patients at high-risk for recurrence. * patients must have adequate bone marrow, renal and hepatic function. exclusion criteria: * patients with recurrent disease. * patients with gog performance status of 3 or 4.

Keywords: endometrial cancer gynecologic cancer vaginal cuff brachytherapy vaginal radiation
effects of the tnf-alpha inhibiton on hemodynamic parameters in resistant hypertension

Conditions: Hypertension

Summary: resistant hypertension (rh) is characterized by high blood pressure (bp) in spite of concurrent use of three or more antihypertensive agents of different classes, combined at optimal doses. currently it has been largely discussed the influence of inflammation in rh. the bp variation promotes increased expression of pro-inflammatory cytokines, such as tumor necrosis factor-alpha, interleukins 1 and 6. it was showed that treatment with tnf-α inhibitor improves bp and endothelial function, and reduces arterial stiffness in patients with rheumatoid arthritis. recently, it was demonstrated that tnf-α levels are increased in rh subjects compared to normotensives. this study aims to assess whether the acute inhibition of tnf-α changes hemodynamic parameters, such as mean bp levels in rh.

this crossover, double-blind study will include 12 resistant hypertensive subjects - regularly followed at the outpatient resistant hypertension clinic/unicamp - which will randomized assigned to (1) saline infusion followed by infliximab infusion (tnf-α inhibitor, 3 mg/kg) and (2) infliximab followed by saline, for two hours and washout of the 40-day period between both infusions. it is expected that the tnf-α inhibition regulates hemodynamic parameters, such as mean bp, cardiac output, total peripheral resistance, which may allow a better rational approach for the rh treatment.

Eligibility criteria:
inclusion criteria: * the diagnosis recommended by the aha statment on resistant hypertension (2008) * a 6-month period clinic follow-up * give written informed consent form exclusion criteria: * secondary hypertension * pseudoresistance hypertension (poor medication adherence and white coat hypertension) * patients with symptomatic ischemic heart disease, impaired renal function, liver disease and history of stroke, myocardial infarction and peripheral vascular diseases * pregnant women * smoking * autoimmune diseases

Keywords: blood pressure inflammation tumor necrosis factor-alpha
the longitudinal approach to acromegaly: a pattern of treatment and comparative effectiveness research

Conditions: Acromegaly

Summary: this study is a prospective, noninteractive, observational, and longitudinal study aimed at assessing the treatment pattern and clinical outcome of acromegaly in china.

the study was designed to answer some of the most important questions about the treatment modalities of acromegaly, the relevance of these treatment modalities to patients' clinical outcomes and the economic impact of treatment programs on patients. these answers may be of great help to the treatment of these populations and may also help to make treatment and related health decisions in the future. this study only collects the patient's medical information during the study and does not interfere with the patient's treatment. each patient will be assigned a unique patient identification number for the study. the sites will maintain a confidential decode list that enables the study staff at the site to link the assigned patient identification number with the patient's medical records for extraction of study-required data. these registries will be maintained following international conference on harmonisation (ich) good clinical practice (gcp) and the respective local privacy laws and requirements.

Eligibility criteria:
inclusion criteria: 1. be able and willing to sign the informed consent form (icf) 2. male, female, age 18-75 years old (including 18 years old and 75 years old). 3. compliance with acromegaly diagnostic criteria: * at least one laboratory or medical record shows that the patient is random gh ≥ 2.5 μg / l * at least one checklist or medical record shows radiographic evidence that the patient has a pituitary tumor exclusion criteria: 1. ectopic secretion of gh or pituitary cancer 2. the patient is diagnosed with other complicated malignancies, or has previously been diagnosed with another malignancy, and there is currently evidence of lesion residue. 3. have a diagnosis of other severe acute or chronic medical or psychiatric conditions that may increase the risk associated with study participation or may interfere with the interpretation of the study results and, in the judgement of the investigator, would make the patient inappropriate for enrollment in this study. 4. be a patient who, in the judgement of the investigator, would be inappropriate for enrollment in this study

Keywords: acromegaly
high-intensity laser therapy improves pain, health status and quality of life in women with fibromyalgia

Conditions: Fibromyalgia

Summary: this study will be conducted to investigate high-intensity laser therapy improves pain, health status and quality of life in women with fibromyalgia


Eligibility criteria:
inclusion criteria: 1. wpi ≥ 7/19 pain sites and sss ≥ 5/12 or wpi between \> 3-6/19 and sss \> 9/12 2. symptoms have been present at a similar level for at least 3 months 3. the patient does not have another disorder that would otherwise sufficiently explain the pain 4. generalized pain, defined as pain in at least four of five regions, is present exclusion criteria: * uncontrolled diabetes * known history of cancer
negative pressure ventilation in paediatric patients during weaning

Conditions: Weaning Failure

Summary: negative pressure ventilation (npv) represent a unique form of noninvasive ventilation using negative pressure by specialized cuirass, that evolve negative pressure on the front size of chest and partially abdomen and facilitate the spontaneous breathing. the benefit of npv beside noninvasive application, is the supreme tolerance of the patient (compared to other forms of noninvasive ventilation - mask, helmet), without the negative impact on enteral feeding tolerance and with the possibility of active physiotherapy. npv could be even combined with oxygentherapy or noninvasive positive pressure ventilation. npv in paediatric patients after extubation could be associated with reduced incidence of weaning failure.

after ethics committee approval and informed consent from legal guardians and fulfilling inclusion criteria, critically ill paediatric patients scheduled for weaning will be randomized (in 1:1 allocation) to npv (interventional group) or standard approach (without npv) after extubation. npv in paediatric patients after extubation could be associated with reduced incidence of weaning failure. the initial setting on npv will be: negative pressure set to -10cmh2o and will proceed for minimal time of 60 minutes after extubation (will proceed longer in case of good tolerance). in case of hypoxaemia, additional oxygentherapy will be administered according to the patients condition primary outcome will be defined as postextubation failure incidence at 60 minutes after extubation (defined as need of noninvasive positive pressure ventilation, intubation, or high-flow oxygen therapy) and the overall incidence of weaning failure during initial 24 hour after extubation. the secondary outcome will be the dynamics of blood gases (arterial or capillary blood sample) during initial 60 minutes after extubation (1. extubation, 2. 60 minutes after extubation) and the need of and amount of artificial oxygentherapy (litres of oxygen per minute, pulse oximetry). another outcome will be the overall cuirass tolerance after 60 minutes and after 24 hours defined by incidence of skin lesions.

Eligibility criteria:
inclusion criteria: * invasive mechanical ventilation * informed consent * scheduled for weaning exclusion criteria: * neuromuscular disorder * mechanical ventilation at home (chronic use) * less than 24 hours after abdominal or thoracic surgery * technical problems with the cuirass - chest drain

Keywords: weaning weaning failure negative pressure ventilation cuirass paediatric patient critical care
effect of dietary fat on glycemic control in type 1 diabetes

Conditions: Type 1 Diabetes

Summary: the purpose of this study is to determine if dietary fat alters insulin requirements in type 1 diabetes.

this cross-over prospective study will require a two day admission to the clinical research center. subjects will undergo closed loop glucose control and will received a diet with controlled macronutrient content.

Eligibility criteria:
inclusion criteria: * type 1 diabetes using insulin pump and cgm exclusion criteria: * renal or hepatic failure * cancer or lymphoma * malabsorption or malnourishment * hypercortisolism * alcoholism or drug abuse * anemia (hematocrit \< 36 in females and \<40 in males) * eating disorder * dietary restrictions * acetaminophen allergy * chronic acetaminophen use * glucocorticoid therapy
autoimmune hepatitis in pediatric patients

Conditions: Autoimmune Hepatitis

Summary: autoimmune hepatitis (aih) is an immune-mediated and inflammatory liver disorder. it is currently divided into types 1 and 2, differentiated and defined by the presence of specific autoantibodies. the objectives are to describe the prevalence and incidence of type 1 and 2 autoimmune hepatitis and to analyze the clinics, biochemical and histopathological profiles at diagnosis and follow-up, initial therapy, response to therapy and long-term follow-up in three italian centers of patients with type 1 and type 2 aih.

background: autoimmune hepatitis (aih) is an immune-mediated and inflammatory liver disorder with typical onset in pediatric age. it is currently divided into types 1 and 2, differentiated and defined by the presence of specific autoantibodies. aih type 1 (aih-1) is characterised by smooth muscle and/or antinuclear autoantibodies (sma/ana) while anti-liver kidney microsomal (anti-lkm) or liver cytosol type 1 (anti-lc1) identified aih type 2 (aih-2). the conventional treatment is based on corticosteroids and azathioprine as first line therapy. the optimal duration is not clear definied, however it should be extended for at least five years due to the frequent relapses. aims of the study: the primary objective is to describe the prevalence and incidence of type 1 and 2 autoimmune hepatitis on a selected italian pediatric population. secondary objectives are to analyze the clinical, biochemical and histopathological profiles at diagnosis and follow-up, type of treatment received, response to therapy and long-term follow-up. methods: the investigators conducted a retrospective and prospective cohort study on patients aged ≤ 18 years who the diagnosis of aih 1 and 2 between 01/01/1989 and 31/12/2019 and were followed in three italian pediatric centers.

Eligibility criteria:
inclusion criteria: * age ≤ 18 years at the time of diagnosis * diagnosis of autoimmune hepatitis type 1 or 2 according to the mieli-vergani score: a pre-treatment score\> 15 or post-treatment\> 17 indicates a definite diagnosis of autoimmune hepatitis; a pre-treatment score between 10 and 15 or post-treatment between 12 and 17 indicates a probable diagnosis. exclusion criteria: * age\> 18 years at the time of diagnosis * presence of other causes of liver disease * presence of overlap syndrome (hepatito-cholangitis)

Keywords: autoimmune hepatitis incidence prevalence immunosuppressive treatmen liver transplantation
microrna 155 levels and periodontal microflora (bacteria and virus) in preeclampsia.

Conditions: Preeclampsia; Chronic Periodontitis

Summary: preeclamptic women with and without chronic periodontitis were recruited for the study. subgingival plaque samples and placental tissue samples(postpartum) were obtained from the participants for the microbial analysis(bacteria, viruses) and mir155 levels and comparison was done among groups. this study was designed in order to evaluate the role of periodontal microorganisms in preeclampsia and to find compare the mir155 levels among participants, so as to check its importance as a biomarker for inflammatory disease like preeclampsia.

four hundred forty five pregnant women, aged 18-35 yrs were selected and were divided into four groups. controls- 145 systemically and periodontally healthy, group a-100 systemically healthy women with chronic periodontitis, group b- 100 preeclamptic women with chronic periodontitis, group c-100 preeclamptic women without chronic periodontitis. age, bmi, socioeconomic status and periodontal parameters such as plaque index(pi), bleeding on probing(bop), probing pocket dept(ppd), clinical attachment level(cal) were recorded. subgingival plaque and placental tissues (postpartum) were collected and assessed for periodontal pathogens such as tannerella forsythia(tf), treponema denticola(td), porphyromonas gingivalis(pg), prevotella intermedia(pi), fusobacterium nucleatum(fn). herpes simplex virus(hsv), ebstein barr virus(ebv), human cytomegalovirus(hcmv). microrna155 levels were also assessed and compared between the groups.

Eligibility criteria:
inclusion criteria: * pregnant women within the age group of 18-35 years with single gestation, having ≥ 20 natural teeth, who did not receive periodontal treatment in last six months and willing to participate in the study were included for the investigation. exclusion criteria: * pregnant women with current use of any form of tobacco, history of alcohol consumption and systemic medications were excluded from the study.

Keywords: periodontal microflora, preeclampsia
tvt versus tot in urinary stress incontinence with no intrinsic sphincter deficiency

Conditions: Female Urinary Stress Incontinence

Summary: the aim of this study is to compare trans-vaginal tape(tvt) and trans-obturator tape(tot) procedure in female urinary stress incontinence with no intrinsic sphincter deficiency.

patients with isolated stress incontinence attending to dr zekai tahir burak woman health teaching and research hospital urogynecology department will be prospectively randomized,by a computer generated randomisation code,to the tvt or tot. the patients will be aware of the type of the surgical procedure before the operation. preoperative evaluation includes clinical history,urinanalysis,pelvic examination qol assessment and urodynamic study. qol included urogenital distress inventory short form (udi-6) and the incontinence impact questionnaire short form( iiq-7).urodynamic study includes cystometry,urethral profilometry and valsalva leak point pressure (vlpp).in all patients,pelvic floor defect will be evaluated according to the pop quantification (popq) staging.to diagnose the occult stress incontinence in patients with pelvic prolapse, a cough test after reducing the prolapse will be performed.patients will be followed up at 6 and 12 months postoperatively.objective cure is defined as a negative cough stress test .negative cough stress test ,but occasional urine leakage during stress will be considered ''improved''. postoperative subjective outcomes will be categorized as follows:cured (udi-6 and iiq-7 postoperative\ preoperative) and worsened (udi-6 and iiq-7 if postoperative\<preoperative).

Eligibility criteria:
inclusion criteria: * women with urinary stress incontinence with no intrinsic sphincter deficiency * women with or without pelvic organ prolapse exclusion criteria: * previous incontinence surgery * urge incontinence or overactive bladder * mixed incontinence * intrinsic sphincter deficiency * body mass index\>35 * un-willing for randomisation

Keywords: tvt,tot,randomized